Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
United States
Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois Duke University Health System, Durham, North Carolina Lysosomal & Rare Disorders Research and Treatment Center, Fairfax, Virginia Australia
Westmead Hospital-Cnr Hawkesbury and Darcy Rds, Westmead, New South Wales Brazil
Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul Germany
SphinCS Clinical Science for LSD, Höchheim Spain
Hospital Quironsalud Zaragoza, Paseo Mariano Renovales Sn, Zaragoza United Kingdom
Royal Free Hospital NHS Trust, London